Istendo

Acetylcysteine, the active ingredient in Istendo, is a mucolytic presented as a solution for endotracheopulmonary use. It helps reduce mucus viscosity in patients with respiratory conditions such as COPD, bronchitis and other chronic airway diseases. GNH USA supplies Istendo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution, and customers benefit from reliable logistics, batch traceability, comprehensive documentation and competitive pricing.

Acetylcysteine is used as a respiratory mucolytic to thin airway secretions in various pulmonary conditions. - Chronic obstructive pulmonary disease (COPD): improves mucus clearance and reduces the frequency of exacerbations. - Bronchitis: facilitates expectoration and eases breathing discomfort. - General mucolysis in respiratory diseases: reduces mucus viscosity to aid airway patency.

Adverse reactions may occur with acetylcysteine administration.

Common Side Effects: - Cough - Throat irritation - Nausea - Headache

Serious or Rare Side Effects: - Anaphylactic reaction - Bronchospasm - Severe skin rash (e.g., Stevens‑Johnson syndrome) - Hepatic enzyme elevation

When using acetylcysteine, consider the following precautions. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor for allergic reactions: discontinue if signs of hypersensitivity appear. - Use with caution in asthma: may provoke bronchospasm. - Avoid concurrent nebulized mucolytics unless advised by a clinician. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in the original container, protect from moisture and light.

Acetylcysteine may interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - Nitroprusside: may enhance hypotensive effect. - Activated charcoal: can reduce acetylcysteine absorption if given simultaneously. - Anticoagulants (e.g., warfarin): may increase bleeding risk.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: may increase risk of ototoxicity. - Other mucolytics: additive effect on mucus clearance may require dose adjustment.